
Sign up to save your podcasts
Or


In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in patients with relapsed/refractory multiple myeloma.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in patients with relapsed/refractory multiple myeloma.
Featured Articles:

11,140 Listeners

141 Listeners

319 Listeners

500 Listeners

75 Listeners

26 Listeners

1,156 Listeners

2 Listeners

363 Listeners

373 Listeners

1 Listeners

48 Listeners

190 Listeners

30 Listeners

4 Listeners